Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Reardon DA, et al. Among authors: shafman td. J Clin Oncol. 2002 Mar 1;20(5):1389-97. doi: 10.1200/JCO.2002.20.5.1389. J Clin Oncol. 2002. PMID: 11870184 Clinical Trial.
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD. Cokgor I, et al. Among authors: shafman td. J Clin Oncol. 2000 Nov 15;18(22):3862-72. doi: 10.1200/JCO.2000.18.22.3862. J Clin Oncol. 2000. PMID: 11078500 Clinical Trial.
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Marks LB, Garst J, Socinski MA, Sibley G, Blackstock AW, Herndon JE, Zhou S, Shafman T, Tisch A, Clough R, Yu X, Turrisi A, Anscher M, Crawford J, Rosenman J; Carolina Conformal Therapy Consortium. Marks LB, et al. J Clin Oncol. 2004 Nov 1;22(21):4329-40. doi: 10.1200/JCO.2004.02.165. J Clin Oncol. 2004. PMID: 15514374 Clinical Trial.
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
Anscher MS, Garst J, Marks LB, Larrier N, Dunphy F, Herndon JE 2nd, Clough R, Marino C, Vujaskovic Z, Zhou S, Dewhirst MW, Shafman TD, Crawford J. Anscher MS, et al. Among authors: shafman td. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):477-82. doi: 10.1016/j.ijrobp.2006.05.031. Epub 2006 Aug 14. Int J Radiat Oncol Biol Phys. 2006. PMID: 16904841
Relating radiation-induced regional lung injury to changes in pulmonary function tests.
Fan M, Marks LB, Lind P, Hollis D, Woel RT, Bentel GG, Anscher MS, Shafman TD, Coleman RE, Jaszczak RJ, Munley MT. Fan M, et al. Among authors: shafman td. Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):311-7. doi: 10.1016/s0360-3016(01)01619-4. Int J Radiat Oncol Biol Phys. 2001. PMID: 11567804 Clinical Trial.
53 results